DiPardo, A., Maglione, V. (2018). Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders. Frontiers in Neuroscience.

O'Sullivan, S., Dev, KK. (2017). Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases. Neuropharmacology. 113, 597-607. (

Czubowicz, K., Jęśko, H., Wencel, P., Lukiw, WJ., Strosznajder, RP. (2019) The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer's Disease and Other Neurodegenerative Disorders. Mol Neurobiol. 56, 5436-5455. (



West, AB. (2017). Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol. 298, 236-245. (  

Atashrazm, F., Dzamko, N. (2016) LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives. Clin Pharmacol. 8, 177-189. (

Trinh, J., Guella, I., Farrer, M. (2014) Disease Penetrance of Late-Onset Parkinsonism: A Meta-analysis. JAMA Neurol. 71, 1535-1539. (

Christensen, K. (2018) LRRK2 exonic variants associated with Parkinson's disease augment phosphorylation levels for LRRK2-Ser1292 and Rab10-Thr73. BioRxiv.



Liu, C.C., Kanekiyo, T., Xu, H., and Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat. Rev. Neurol. 9, 106–118. (

Mahley, R.W., Huang, Y. (2012). Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron 76, 871-885. (

Verghese, P.B., Castellano, J.M., and Holtzman, D.M. (2011). Roles of apolipoprotein E in Alzheimer's Disease and other neurological disorders. Lancet Neurol. 10, 241–252. (

Caselli, R.J., Dueck, A. C., Osborne, D., Sabbagh, M.N., Connor, D.J., Ahern, G.L., Baxter, L.C., Rapcsack, S.Z., Shi, J., Woodruff, B.K., et al. (2009). Longitudinal modeling of age-related memory decline and the ApoE Ɛ4 effect. N. Engl. J. Med. 361, 255-263. (

Raber, J., Huang, Y., Ashford, J.W. (2004). ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25, 641-650. (